Structure-based repurposing of FDA-approved drugs as TNF-α inhibitors

Chung Hang Leung*, Daniel Shiu Hin Chan, Maria Hiu Tung Kwan, Zhen Cheng, Chun Yuen Wong, Guo Yuan Zhu, David W F FONG, Edmond Dik Lung MA

*Corresponding author for this work

Research output: Contribution to journalJournal articlepeer-review

44 Citations (Scopus)


Old dogs, new tricks! We applied structure-based virtual screening methods to identify small-molecule inhibitors of tumor necrosis factor-α (TNF-α) from a database of 3000 US Food and Drug Administration (FDA)-approved drugs. Darifenacin (Enablex) and ezetimibe (Zetia) were identified as direct TNF-α inhibition, representing only the fifth and sixth examples of small-molecule TNF-α inhibitors.

Original languageEnglish
Pages (from-to)765-768
Number of pages4
Issue number5
Publication statusPublished - 2 May 2011

Scopus Subject Areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry

User-Defined Keywords

  • Approved drugs
  • Drug discovery
  • Inhibitors
  • Tumor necrosis factor
  • Virtual screening


Dive into the research topics of 'Structure-based repurposing of FDA-approved drugs as TNF-α inhibitors'. Together they form a unique fingerprint.

Cite this